TITLE

Avicena to conduct trial for Huntington's disease drug

PUB. DATE
August 2007
SOURCE
PharmaWatch: CNS;Aug2007, Vol. 6 Issue 8, p10
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports that biotechnology company Avicena Group Inc. will conduct a Phase III trial for its novel drug HD-02 for the treatment of Huntington's disease. The said study will evaluate HD-02 in a range of doses from 10 to 40 grams per day to determine the optimal dose of the drug that will provide a maximum efficacy, safety, and tolerability.
ACCESSION #
26059148

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics